RTW Venture Fund Limited specializes in identifying transformative assets with high growth potential across the life sciences, biopharmaceutical and medical technology sectors. The fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited

RTW is a life sciences investment and innovation firm. Headquartered in New York with offices in London and Shanghai, we invest across the full lifecycle of companies including company creation, early stage venture capital, alternative financing, and public company investments.

Biomea Fusion

Milestone Pharmaceuticals

NeoGenomics

Orchard Therapeutics

Prometheus Biosciences

2seventy bio

Allakos

Athira Pharma

Avidity Biosciences

Solid Biosciences

Stoke Therapeutics

Third Harmonic Bio

UroGen Pharma

C4 Therapeutics

CinCor Pharma

GH Research

immatics biotechnologies

Immunic Therapeutics

Rocket Pharmaceuticals

Roivant Sciences

Ventyx Biosciences

Science 37

Pulmonx

REGENXBIO

Renovacor

Immunocore

RTW Investments, LP

On National Intern Day we want to recognize our 2023 summer intern class.

Our exceptional group of interns has been actively engaged in various summer projects, ranging from research and development tracking to fundraising coordination, data organization, and therapeutic asset research. We extend our gratitude to Stela Sota, Halle Fiedler, Yifei Zhang, Sophie Takmopoulos, Karan Naik, Vincent Masto, and Yen-Der Li, MD, PhD for their dedicated efforts and hard work!

#Interns #RTWInterns #NationalInternday #InternAppreciation

This morning we announced Igor Splawski has joined RTW’s Yarrow Biotechnology as Chief Scientific Officer. Thanks to Lei Lei Wu for the Endpoints News Peer Review piece highlighting Igor’s unique style and deep expertise. Welcome to the team, Igor!

https://lnkd.in/gZPCXztt

Our managing director and CIO, Roderick Wong recently sat down with Daniel Coatsworth for AJ Bell’s Money and Markets podcast. The two discussed biotech M&A trends, our approach to investing in therapies targeting rare diseases, and some of the companies Rod’s excited about right now. The full episode featuring insights on the mortgage market and higher interest rate impacts on other sectors can be found at the below link. Rod’s portion starts just before the 27-minute mark. 

#biotech #investing #lifesciences 

https://lnkd.in/efJMxFJN

Investing in life sciences means not only believing in the power of science but understanding it. Our team of scientists, investors, and entrepreneurs digs deep to identify the most promising innovations and foster them to ensure they have the best chance of creating real life-changing impact on patients. Hear more about how science shapes our approach to investing. Featuring voiceover by our very own Hanah Gershkowitz.

Our purpose goes beyond short-term financial gains. It’s about powering the next innovations that will transform lives. Hear more about why we do what we do through the voice of our own Paula Boone.

Our culture at RTW is shaped by our people, our values, and the passion we share for powering innovative science to impact millions of lives. Hear more about what it’s like to work at RTW as told by our people.

#lifesciences #culture #investing #biotech

#ICYMI: Roderick Wong recently sat down with Capital Allocators’ Ted Seides to share his views on life sciences investing, the growth and evolution of RTW over the years, and some of the lessons he’s learned along the way. 
https://lnkd.in/eJjekwvm

#lifesciences #biotech #investing

Congrats to the ACELYRIN, INC. team on its Nasdaq debut. We're proud to continue to support the company in its mission to develop treatments for patients with inflammatory conditions.

	Mar '21	Jun '21	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Jun '24
net income	-9.07M -	-18.14M 100.00%	-23.10M 27.33%	-23.10M 0%	-51.93M 124.80%	-51.93M 0%	32.21M 162.03%	32.21M 0%	16.25M 49.57%	16.25M 0%	25.35M 56.05%	25.35M 0%	85.82M 238.55%
depreciation and amortization
deferred income tax
stock based compensation
change in working capital	9.96M -	19.91M 100.00%	9.42M 52.69%	9.42M 0%	-12.30M 230.59%	-50.37K 99.59%	2.47M 4,994.78%	2.47M 0%	-1.40M 156.76%	-1.40M 0%	-2.82M 101.65%	-2.82M 0%	55.48M 2,066.00%
accounts receivables	180.52K -	361.04K 100%	234.92K 34.93%	234.92K 0%	-50.37K 121.44%	-50.37K 0%	2.47M 4,994.78%	2.47M 0%	-1.40M 156.76%	-1.40M 0%	-1.16M 17.02%	-1.16M 0%	-6.79M 484.33%
inventory
accounts payables		18.86M -											62.10M -
other working capital	9.78M -	696.46K 92.88%	9.19M 1,218.90%	9.19M 0%	-12.25M 233.38%						-1.66M -	-1.66M 0%	166.19K 110.01%
other non cash items	-13.93M -	-5.67M 59.34%	4.29M 175.79%	4.29M 0%	67.71M 1,476.95%	55.46M 18.09%	-32.98M 159.47%	-32.98M 0%	10.18M 130.87%	10.18M 0%	-30.79M 402.38%	-30.79M 0%	-135.05M 338.69%
net cash provided by operating activities	-13.05M -	15.32M 217.41%	-9.39M 161.26%	-9.39M 0%	3.48M 137.07%	3.48M 0%	1.70M 51.23%	1.70M 0%	25.03M 1,374.79%	25.03M 0%	-8.26M 132.99%	-8.26M 0%	6.26M 175.77%
investments in property plant and equipment													-2.00 -
acquisitions net
purchases of investments		-137.55M -											-337.66M -
sales maturities of investments		96.12M -											258.94M -
other investing activites													-25.64M -
net cash used for investing activites		-41.42M -											-104.35M -
debt repayment
common stock issued		36.44M -											108.42M -
common stock repurchased	-2.49M -	-4.97M 100%									-1.05M -	-1.05M 0%	-11.34M 983.43%
dividends paid
other financing activites	18.22M -	18.22M 0.00%	3.81M 79.06%	3.81M 0%
net cash used provided by financing activities	15.73M -	31.46M 100.00%	3.81M 87.88%	3.81M 0%							-1.05M -	-1.05M 0%	97.08M 9,374.79%
effect of forex changes on cash
net change in cash	2.68M -	13.46M 401.81%	-5.57M 141.39%	-5.57M 0%	3.48M 162.46%	3.48M 0%	1.70M 51.23%	1.70M 0%	25.03M 1,374.79%	25.03M 0%	-9.30M 137.17%	-9.30M 0%	-2.71M 70.83%
cash at beginning of period		4.55M -	29.95M 557.76%			22.29M -	25.77M 15.61%						9.47M -
cash at end of period	2.68M -	18.01M 571.57%	24.38M 35.34%	-5.57M 122.85%	3.48M 162.46%	25.77M 640.49%	27.46M 6.59%	1.70M 93.82%	25.03M 1,374.79%	25.03M 0%	-9.30M 137.17%	-9.30M 0%	6.76M 172.64%
operating cash flow	-13.05M -	15.32M 217.41%	-9.39M 161.26%	-9.39M 0%	3.48M 137.07%	3.48M 0%	1.70M 51.23%	1.70M 0%	25.03M 1,374.79%	25.03M 0%	-8.26M 132.99%	-8.26M 0%	6.26M 175.77%
capital expenditure													-2.00 -
free cash flow	-13.05M -	15.32M 217.41%	-9.39M 161.26%	-9.39M 0%	3.48M 137.07%	3.48M 0%	1.70M 51.23%	1.70M 0%	25.03M 1,374.79%	25.03M 0%	-8.26M 132.99%	-8.26M 0%	6.26M 175.77%

COM:RTWFUNDS

RTW Funds

Last Close

1.48

25/11 08:01

Market Cap

502.74M

Beta: -

Volume Today

21.23K

Avg: -

Preview